IP Library Granted Patent US 7,824,859
Granted Patent B2
US 7,824,859 · App. 11/476,893 · Granted Nov 2, 2010

Methods for detection of a target nucleic acid by forming a cleavage structure using an RNA polymerase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,824,859
App. No.
11/476,893
Granted
Nov 2, 2010
Kind
B2
Abstract

The invention relates to compositions and methods for generating a signal indicative of the presence of a target nucleic acid in a sample, where the compositions and methods include an RNA polymerase, a FEN nuclease, and a probe.

Claims (47)

1. A composition for generating a signal indicative of the presence of a target nucleic acid sequence in a sample, the composition comprising an RNA polymerase, a FEN nuclease, and a probe that is complementary to the target nucleic acid.

2. The composition of claim 1 , further comprising the target nucleic acid.

3. The composition of claim 1 , wherein the probe has a 5′ flap.

4. The composition of claim 3 , wherein the 5′ region of the probe is non complementary to the target nucleic acid.

5. The composition of claim 1 ; wherein the probe comprises: at least one labeled moiety capable of providing a signal.

6. The composition of claim 1 , wherein the probe comprises a pair of interactive signal generating labeled moieties effectively positioned to quench the generation of a detectable signal, the labeled moieties being separated by a site susceptible to FEN nuclease cleavage.

7. The composition of claim 6 , wherein the pair of interactive signal generating moieties comprises a quencher moiety and a fluorescent moiety.

8. The composition of claim 1 , further comprising an upstream oligonucleotide primer, wherein the upstream oligonucleotide primer hybridizes upstream of the probe and is extended by the RNA polymerase.

9. The composition of claim 8 , further comprising a reverse primer.

10. The composition of claim 1 , wherein the FEN nuclease is selected from the group consisting of FEN nuclease enzyme derived from Archaeglobus fulgidus, Methanococcus jannaschii, Pyrococcus furiosus , Taq, Tfl and Bca.

11. The composition of claim 1 , wherein the RNA polymerase is an RNA dependent polymerase.

12. The composition of claim 1 , wherein the RNA polymerase is a DNA dependent polymerase.

13. The composition of claim 1 , wherein the RNA polymerase is selected from the group consisting of: T7-RNA polymerase, SP6-RNA polymerase, T3 RNA polymerase, and NS5B RNA polymerase.

14. The composition of claim 1 , wherein the RNA polymerase is thermostable.

15. A kit for generating a signal indicative of the presence of a target nucleic acid sequence in a sample, the composition comprising an RNA polymerase, a FEN nuclease, and a probe that is complementary to the target nucleic acid.

16. The kit of claim 15 , wherein the probe comprises at least one labeled moiety capable of providing a signal.

17. The kit of claim 15 , wherein the probe comprises a pair of interactive signal generating labeled moieties effectively positioned to quench the generation of a detectable signal, the labeled moieties being separated by a site susceptible to FEN nuclease cleavage.

18. The kit of claim 17 , wherein the pair of interactive signal generating moieties comprises a quencher moiety and a fluorescent moiety.

19. The kit of claim 15 , further comprising an upstream oligonucleotide primer, wherein the upstream oligonucleotide primer hybridizes upstream of the probe and is extended by said RNA polymerase.

20. The kit of claim 19 , further comprising a reverse primer.

21. The kit of claim 15 , wherein the FEN nuclease is selected from the group consisting of FEN nuclease enzyme derived from Archaeglobus fulgidus, Methanococcus jannaschii, Pyrococcus furiosus , Taq, Tfl and Bca.

22. The kit of claim 15 , wherein the RNA polymerase is T7-RNA polymerase, SP6-RNA polymerase, T3 RNA polymerase or NS5B RNA polymerase.

23. The kit of claim 15 , wherein the RNA polymerase is thermostable.

24. The kit of claim 15 , wherein the RNA polymerase is an RNA dependent RNA polymerase.

25. The kit of claim 15 , wherein the RNA polymerase is a DNA dependent RNA polymerase.

26. A method of generating a signal indicative of the presence of a target nucleic acid sequence in a sample, comprising forming a cleavage structure by incubating a sample comprising a target nucleic acid sequence with an RNA polymerase and cleaving the cleavage structure with a FEN nuclease to generate a signal, wherein generation of the signal is indicative of the presence of a target nucleic acid sequence in the sample.

27. A method of detecting or measuring a target nucleic acid sequence, comprising forming a cleavage structure by incubating a sample comprising a target nucleic acid sequence with an RNA polymerase, cleaving the cleavage structure with a FEN nuclease to release a nucleic acid fragment and detecting and/or measuring the release of the fragment as an indication of the presence of the target sequence in the sample.

28. The method of claim 26 , wherein the RNA polymerase is thermostable.

29. The method of claim 26 , wherein the RNA polymerase is T7-RNA polymerase, SP6-RNA polymerase, T3 RNA polymerase or NS5B RNA polymerase.

30. The method of claim 26 , wherein the FEN nuclease is a flap-specific nuclease.

31. The method of claim 26 , wherein the FEN nuclease is thermostable.

32. The method of claim 26 , wherein a cleavage structure is formed comprising at least one labeled moiety capable of providing a signal.

33. The method of claim 26 , wherein a cleavage structure is formed comprising a pair of interactive signal generating labeled moieties effectively positioned to quench the generation of a detectable signal, the labeled moieties being separated by a site susceptible to FEN nuclease cleavage, thereby allowing the nuclease activity of the FEN nuclease to separate the first interactive signal generating labeled moiety from the second interactive signal generating labeled moiety by cleaving at the site susceptible to FEN nuclease, thereby generating a detectable signal.

34. The method of claim 33 , wherein the pair of interactive signal generating moieties comprises a quencher moiety and a fluorescent moiety.

35. The method of claim 26 , wherein a cleavage structure comprises an RNA extension product and a downstream probe with a 5′ flap.

36. A method for detecting a target nucleic acid sequence in a sample, comprising: mixing a probe, a target nucleic acid having a promoter region, a FEN nuclease and an RNA polymerase, under conditions which are permissive for the steps of (i) binding of the RNA polymerase to the promoter region in the target nucleic acid sequence and annealing of the probe to the target, (ii) synthesizing an RNA polymerase extension product, (iii) forming a cleavage structure, and (iv) and cleaving the cleavage structure with the FEN nuclease and detecting and/or measuring the release of labeled fragments or cleavage of the probe as an indication of the presence of the target sequence in the sample.

37. A method for detecting a target nucleic acid sequence in a sample, comprising: mixing a probe, a target nucleic acid, a FEN nuclease, a primer and an RNA polymerase, under conditions which are permissive for the steps of (i) annealing of the primer and probe to the target nucleic acid, (ii) synthesizing an RNA polymerase extension product from said primer, (iii) forming a cleavage structure, and (iv) and cleaving the cleavage structure with the FEN nuclease and detecting and/or measuring the release of labeled fragments or cleavage of the probe as an indication of the presence of the target sequence in the sample.

38. The method of claim 36 or 37 , wherein the FEN nuclease is selected from the group consisting of FEN nuclease enzyme derived from Archaeglobus fulgidus, Methanococcus jannaschii, Pyrococcus furiosus , Taq, Tfl and Bca.

39. The method of claim 36 or 37 , wherein the RNA polymerase is thermostable.

40. The method of claim 36 or 37 , wherein the RNA polymerase is T7-RNA polymerase, SP6-RNA polymerase, T3 RNA polymerase or NS5B RNA polymerase.

41. The method of claim 36 or 37 , wherein the probe comprises at least one labeled moiety capable of providing a signal.

42. The method of claim 36 or 37 , wherein the probe comprises a pair of interactive signal generating labeled moieties effectively positioned to quench the generation of a detectable signal, the labeled moieties being separated by a site susceptible to FEN nuclease cleavage, thereby allowing the nuclease activity of the FEN nuclease to separate the first interactive signal generating labeled moiety from the second interactive signal generating labeled moiety by cleaving at the site susceptible to FEN nuclease, thereby generating a detectable signal.

43. The method of claim 42 , wherein the pair of interactive signal generating moieties comprises a quencher moiety and a fluorescer moiety.

44. The method of claim 36 or 37 , wherein the step of detecting and/or measuring the release of labeled fragments comprises detecting a change in fluorescence between an interactive pair of labels.

45. The method of claim 36 or 37 , wherein the RNA polymerases displaces at least a portion of the downstream probe.

46. The method of claim 36 or 37 , wherein the probe has a 5′ flap.

47. The method of claim 36 or 37 , wherein the RNA polymerase polymerizes nucleotides complementary to a length of the target sufficient to form a cleavage structure so that the polymerized complementary RNA is adjacent at its 3′ end to the probe.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
EIGHTH SUPPLEMENT TO PATENT SECURITY AGREEMENT Recorded Mar 26, 2009
From: CYTYC CORPORATION; HOLOGIC, INC.
To: GOLDMAN SACHS CREDIT PARTNERSL.P.
Reel/Frame 022456/0947 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2008
From: STRATAGENE CALIFORNIA
To: HOLOGIC INC.
Reel/Frame 021976/0268 →